Cabergoline: an advance in dopaminergic therapy.
Bevan
J S
JS
Department of Endocrinology, Aberdeen Royal Infirmary, UK.
Davis
J R
JR
D000077465:Cabergoline; D015259:Dopamine Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004873:Ergolines / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy* / Q000378:metabolism; D010349:Patient Compliance; D011247:Pregnancy; D011388:Prolactin / Q000378:metabolism*
D015259:Dopamine Agents; D004873:Ergolines; D011388:Prolactin; D000077465:Cabergoline